ISSN: 2381-8727



当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得


Results from A Longitudinal Cohort and Mendelian Randomization Study Show A Relationship Between the Age at Diabetes Beginning or the Length of Diabetes and the Risk of Developing Pancreatic Cancer Later

Bayong Chen

Background: The study aims to estimate the incidence of pancreatic cancer in people with new-onset type 2 diabetes (T2DM) and examine the connection between pancreatic cancer risk, age at diagnosis, and duration of diabetes.

Methods: Mendelian randomization (MR) in the east-Asian population and this longitudinal cohort study with 428,362 new-onset T2DM patients in Shanghai were used to investigate the association. All patients' and subgroups' incidence rates of pancreatic cancer were calculated and compared to the general population.

Result: During eight years of follow-up, a total of 1056 incident cases of pancreatic cancer were identified. T2DM patients had a standardized incidence ratio (SIR) of 154 (95% CI, 145–164), which was higher than the general population's annual pancreatic cancer incidence rate of 5528/100,000 person years. The older groups with T2DM had a significantly higher incidence of pancreatic cancer, which increased with age. However, the 20–54-year-old group had a higher SIR of 573 (95% CI, 449–722) and a relative risk of pancreatic cancer that was inversely related to age of T2DM onset. Any duration of diabetes was associated with an increased risk of pancreatic cancer. Pancreatic cancer was linked to fasting blood glucose levels below 10 mmol/L. T2DM had a positive correlation with the risk of pancreatic cancer, according to MR analysis.

Interpretation: Efforts toward early and close follow-up programs, particularly in people with young-onset T2DM, and the improvement of glucose control might be effective strategies for improving the detection of pancreatic cancer and the outcomes of its treatment.